Nutra Pharma Announces Shareholder Conference Call Scheduled for Wednesday, February 14, 2007.

BOCA RATON, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has scheduled a shareholder conference call for today at 4:00PM EST to further explain the Company's recent news and continued progress. The call will feature a presentation by Rik J. Deitsch, Chairman and CEO of Nutra Pharma, along with presentations by Stewart Lonky, MD, a Director of the Company, and Neil Roth, President of Designer Diagnostics. The presentations will be followed by a 15 minute question and answer session.

"The Company has been moving forward quickly as is clearly evidenced from all of our recent press releases," commented Mr. Deitsch. "We would like to invite all of our shareholders and other interested parties to join us on this conference call so that we may explain our progress and the short-term and mid-term implications of these accomplishments," he added.

For details on the call as well as dial-in information, please visit the Nutra Pharma website at: http://www.NutraPharma.com.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The shareholder conference call scheduled for February 14, 2007 should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.